BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis

EPA:BLC • FR0000035370

26.05 EUR
-0.25 (-0.95%)
Last: Feb 27, 2026, 05:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

Overall BLC gets a fundamental rating of 4 out of 10. We evaluated BLC against 32 industry peers in the Health Care Providers & Services industry. BLC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BLC has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • BLC had positive earnings in the past year.
  • BLC had a positive operating cash flow in the past year.
  • Of the past 5 years BLC 4 years were profitable.
  • Each year in the past 5 years BLC had a positive operating cash flow.
BLC.PA Yearly Net Income VS EBIT VS OCF VS FCFBLC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

1.2 Ratios

  • With a Return On Assets value of 0.08%, BLC is not doing good in the industry: 78.13% of the companies in the same industry are doing better.
  • With a Return On Equity value of 0.74%, BLC is not doing good in the industry: 71.88% of the companies in the same industry are doing better.
  • The Return On Invested Capital of BLC (6.43%) is better than 65.63% of its industry peers.
  • BLC had an Average Return On Invested Capital over the past 3 years of 6.14%. This is in line with the industry average of 6.99%.
  • The last Return On Invested Capital (6.43%) for BLC is above the 3 year average (6.14%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.08%
ROE 0.74%
ROIC 6.43%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
BLC.PA Yearly ROA, ROE, ROICBLC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • The Profit Margin of BLC (0.11%) is worse than 78.13% of its industry peers.
  • In the last couple of years the Profit Margin of BLC has declined.
  • The Operating Margin of BLC (8.21%) is better than 68.75% of its industry peers.
  • BLC's Operating Margin has been stable in the last couple of years.
  • BLC's Gross Margin of 67.80% is fine compared to the rest of the industry. BLC outperforms 75.00% of its industry peers.
  • In the last couple of years the Gross Margin of BLC has grown nicely.
Industry RankSector Rank
OM 8.21%
PM (TTM) 0.11%
GM 67.8%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
BLC.PA Yearly Profit, Operating, Gross MarginsBLC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
  • The number of shares outstanding for BLC remains at a similar level compared to 1 year ago.
  • BLC has about the same amout of shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BLC has been reduced compared to a year ago.
BLC.PA Yearly Shares OutstandingBLC.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
BLC.PA Yearly Total Debt VS Total AssetsBLC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • BLC has an Altman-Z score of 1.41. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
  • BLC has a Altman-Z score (1.41) which is comparable to the rest of the industry.
  • BLC has a debt to FCF ratio of 12.90. This is a negative value and a sign of low solvency as BLC would need 12.90 years to pay back of all of its debts.
  • The Debt to FCF ratio of BLC (12.90) is worse than 62.50% of its industry peers.
  • A Debt/Equity ratio of 5.29 is on the high side and indicates that BLC has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 5.29, BLC is doing worse than 84.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 5.29
Debt/FCF 12.9
Altman-Z 1.41
ROIC/WACC1.26
WACC5.12%
BLC.PA Yearly LT Debt VS Equity VS FCFBLC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • BLC has a Current Ratio of 1.38. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
  • BLC's Current ratio of 1.38 is fine compared to the rest of the industry. BLC outperforms 75.00% of its industry peers.
  • BLC has a Quick Ratio of 1.18. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of BLC (1.18) is better than 78.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.18
BLC.PA Yearly Current Assets VS Current LiabilitesBLC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • BLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 158.33%, which is quite impressive.
  • BLC shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.37% yearly.
  • The Revenue has been growing slightly by 6.35% in the past year.
  • Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.75% on average over the next years.
  • BLC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.69% yearly.
EPS Next Y-4.33%
EPS Next 2Y0.96%
EPS Next 3Y6.75%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BLC.PA Yearly Revenue VS EstimatesBLC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BLC.PA Yearly EPS VS EstimatesBLC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 372.14, which means the current valuation is very expensive for BLC.
  • Based on the Price/Earnings ratio, BLC is valued a bit more expensive than the industry average as 78.13% of the companies are valued more cheaply.
  • BLC is valuated expensively when we compare the Price/Earnings ratio to 27.11, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 12.96, BLC is valued correctly.
  • BLC's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BLC is cheaper than 75.00% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.13, BLC is valued rather cheaply.
Industry RankSector Rank
PE 372.14
Fwd PE 12.96
BLC.PA Price Earnings VS Forward Price EarningsBLC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 93.75% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BLC is valued cheaper than 81.25% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.02
EV/EBITDA 5.74
BLC.PA Per share dataBLC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.96%
EPS Next 3Y6.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BLC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BASTIDE LE CONFORT MEDICAL

EPA:BLC (2/27/2026, 5:29:29 PM)

26.05

-0.25 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-12
Earnings (Next)05-14
Inst Owners11.61%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap191.99M
Revenue(TTM)491.18M
Net Income(TTM)533.00K
Analysts77.14
Price Target36.21 (39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP106.75%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-26.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 372.14
Fwd PE 12.96
P/S 0.39
P/FCF 6.02
P/OCF 2.09
P/B 2.66
P/tB N/A
EV/EBITDA 5.74
EPS(TTM)0.07
EY0.27%
EPS(NY)2.01
Fwd EY7.72%
FCF(TTM)4.32
FCFY16.6%
OCF(TTM)12.48
OCFY47.9%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.93
Profitability
Industry RankSector Rank
ROA 0.08%
ROE 0.74%
ROCE 8.75%
ROIC 6.43%
ROICexc 6.81%
ROICexgc 12.17%
OM 8.21%
PM (TTM) 0.11%
GM 67.8%
FCFM 6.49%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 5.29
Debt/FCF 12.9
Debt/EBITDA 3.78
Cap/Depr 99.07%
Cap/Sales 12.23%
Interest Coverage 250
Cash Conversion 91.09%
Profit Quality 5980.3%
Current Ratio 1.38
Quick Ratio 1.18
Altman-Z 1.41
F-Score8
WACC5.12%
ROIC/WACC1.26
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y-4.33%
EPS Next 2Y0.96%
EPS Next 3Y6.75%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
EBIT growth 1Y18.78%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year137.78%
EBIT Next 3Y39.06%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%

BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ

Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.


Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a valuation rating of 4 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?

BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.


What is the expected EPS growth for BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?

The Earnings per Share (EPS) of BASTIDE LE CONFORT MEDICAL (BLC.PA) is expected to decline by -4.33% in the next year.


Can you provide the dividend sustainability for BLC stock?

The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 106.75%.